Updates on CXO Telecom Fraud: Controlling Shareholder Advances Nearly RMB 90 Million; BeiGene's PD-1 Inhibitor Receives FDA Approval
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Johnson & Johnson
Medical Device R&D and Manufacturer
CHIATAI TIANQING
High-quality pharmaceuticals research, production, and sales provider
Follow-up on the CXO Telecom Fraud Incident
On March 15, Hepalink announced that Tido Italy had fallen victim to a telecom fraud scheme perpetrated by a criminal gang, involving an amount of more than 11.7 million euros. To safeguard the interests of the company and its investors, the company received an advance payment from实际控制人李锂 through Shenzhen Lerentech Co., Ltd., totaling RMB 89.8096 million (equivalent to 11.74 million euros).
The Second China-Produced PD-1 Lands in the U.S. Market.
On March 14, BeOne Medicines announced that its PD-1 antibody Tislelizumab had been approved by the FDA for marketing. It is used to treat patients with unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma who have previously undergone systemic therapy.
In the past day, what are the hot topics worth paying attention to in the pharmaceutical markets at home and abroad? Let Amino take you through them.
/ 01 /
Market Express
1) HEPALIS Receives Advance Payment from Actual Controller
On March 15, Hepalink announced that Tendo Italia suffered a telecommunication fraud conducted by a criminal gang, involving an amount of more than 11.7 million euros. To protect the interests of the company and its investors, the company received an advance payment from Li Li, the actual controller, through Shenzhen Lerentech Co., Ltd., totaling RMB 89.8096 million (equivalent to 11.74 million euros).
2) Hansoh Pharma Introduces Primus Bispecific ADC
On March 14, Hansoh Pharmaceutical announced that it had reached a cooperation agreement with Premas Biotech to obtain the global rights to the latter's EGFR/cMet bispecific ADC drug PM1080.
/ 02 /
Pharmaceuticals and Medical Devices Updates
1) Siconra 3HP-2827 Tablets Approved for Clinical Trials
On March 15, according to the CDE official website, Sicanruqi's 3HP-2827 tablets have been approved for clinical trials, and are proposed to conduct research on the treatment of FGFR2-abnormal tumor patients with single-agent or combination chemotherapy and/or immunotherapy drugs.
2) Johnson & Johnson TAR-200 Approved for Clinical Use
On March 15, according to the CDE website, Johnson & Johnson's TAR-200 has been approved for clinical trials, aiming to conduct research on the treatment of high-risk non-muscle-invasive bladder cancer.
3) Novo Nordisk's Etavopivat Approved for Clinical Trials
On March 15, according to the CDE official website, Novo Nordisk's Etavopivat was approved for clinical trials, intending to conduct research on the treatment of thalassemia.
4) ABBV-383 Infusion Solution by AbbVie Approved for Clinical Use
On March 15, according to the CDE official website, AbbVie's ABBV-383 infusion solution was approved for clinical trials, intended to conduct research on the treatment of multiple myeloma.
5) CSPC Pharmaceutical Group's SYH2039 Tablet Approved for Clinical Trials
On March 15, according to the CDE official website, SYH2039 tablets developed by CSPC Pharmaceutical Group were approved for clinical trials, aiming to conduct research on the treatment of advanced malignant tumors.
6) Daiichi Sankyo's DS-8201a Approved for Clinical Use
On March 15, according to the CDE official website, Daiichi Sankyo's DS-8201a was approved for clinical trials, intended for use in HER2-expressing (IHC 3+/IHC 2+), mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer.
7) CHIATAI TIANQING Announces Development Progress of MASH Products Lanifibranor and TQA2225
On March 15, CHIATAI TIANQING announced that Lanilanuo (pan-PPAR agonist) and TQA2225 (recombinant human FGF21-Fc fusion protein), which were jointly developed, are currently undergoing Phase III and Phase II clinical trials in China, respectively, for the treatment of metabolic dysfunction-associated steatohepatitis.
8) BeOne Medicines' PD-1 Granted FDA Approval for Market Launch
On March 14, BeOne Medicines announced that its PD-1 antibody Tislelizumab had been approved by the FDA for marketing. It is used to treat patients with unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma who have previously undergone systemic therapy.
9) Henlius' EGFR-Targeted ADC Candidate HLX42 Completes First Patient Dosing in Phase I Clinical Trial
On March 14, Henlius announced that the Phase I clinical study of HLX42 Injection, an EGFR-targeted antibody-drug conjugate developed in collaboration with Yilian Biotechnology for the treatment of advanced/metastatic solid tumors, has completed the first patient dosing in China.
10) MEK Inhibitor from Kezhou Pharmaceuticals Approved for Marketing
On March 15, according to the NMPA official website, the MEK inhibitor Tolerametinib capsule developed by Kezhou Pharmaceutical was approved for marketing in China. It is suitable for patients with advanced melanoma who have NRAS mutations and failed to respond to anti-PD-1/PD-L1 treatments.
/ 03 /
Overseas Pharmaceutical News
1) The World's First MASH Therapy Approved for Marketing
On March 14, Madrigal announced that its innovative drug resmetirom received accelerated FDA approval for market release in the United States. It is to be used in combination with diet and exercise for the treatment of adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and moderate to severe liver fibrosis (stages F2 to F3). According to the press release, this is the first MASH therapy to receive FDA approval.
Text by Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
